Stemcyte cleared to study umbilical cord blood stem cell therapy for post-COVID syndrome

Aug. 30, 2022

Stemcyte Inc. has received IND approval from the FDA for a phase II trial using umbilical cord blood stem cell therapy for post-COVID syndrome, or long COVID.

BioWorld Science Regulatory Stem cells Immune Coronavirus FDA IND Phase II

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 21, 2025.

Coinfections and diversity paint the many shades of HIV cure

BioWorld

We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...

Engineered IL-18 variants with improved drug-like properties show promise for cancer immunotherapy

BioWorld Science

Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in promoting antitumor immunity by activating T and natural killer (NK) cells....

For big pharma, China is a shopper’s dream

BioWorld

Big pharma is increasingly shopping in China to fill its pipelines as it faces looming patent cliffs on major blockbusters coupled with growing pricing...